<DOC>
	<DOCNO>NCT00083876</DOCNO>
	<brief_summary>This study design evaluate whether combination chemotherapy `` anti-angiogenesis '' therapy thalidomide equal superior autologous transplantation treatment multiple myeloma .</brief_summary>
	<brief_title>D.T . PACE Versus High Dose Melphalan Autologous Transplant Patients With Previously Treated Multiple Myeloma</brief_title>
	<detailed_description>All patient receive two cycle , 4-6 week apart , combination chemotherapy drug ( regimen call D.T . PACE ) collection peripheral blood stem cell . D.T . PACE consist 6 chemotherapy drug ( Dexamethasone , Thalidomide , CisPlatin , Adriamycin , Cyclophoshamide , Etoposide ) . Four six week last cycle D.T . PACE , patient evidence myeloma progression randomly assign receive 1 ) Autologous Transplant describe 2 ) Additional cycle D.T . PACE . Since known time treatment best , patient place chance one two group . If test show myeloma remission time randomization , 2 additional cycle D.T . PACE give . If myeloma remission , 2 additional cycle D.T . PACE give , myeloma re-assessed . If patient myeloma protein decrease 90 % since baseline better , 2 cycle give . If decrease much gotten bad , patient offer autologous transplantation . Patients financial coverage transplant , inadequate stem cell collection support two transplant , randomize proceed directly treatment 2 , continue D.T . PACE . If determine myeloma respond adequately first 2 cycle D.T . PACE , patient randomize proceed directly autologous transplant . Between 2 4 month first PBSC transplant , patient undergo second course high-dose Melphalan PBSC transplant . In order patient receive maximum possible benefit , patient may `` cross-over '' treatment arm myeloma go complete remission time myeloma progress randomization . When physician feel maximum benefit chemotherapy receive ( best partial complete remission ) last phase study start , maintenance . Patients randomly assign receive either low dose ( 50 mg ) high dose ( 200 mg ) thalidomide dexamethasone .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients must previously treat ( &gt; 1 cycle prior therapy ) , active multiple myeloma require treatment . Patients receive &gt; 450 mg/m2 prior Adriamycin therapy eligible , however , Adriamycin delete DT PACE regimen patient . Patients must measurable disease define one following : serum monoclonal protein &gt; /= 1.0 mg/dl , OR urine monoclonal protein &gt; /= 1.0 grams/24 hour , OR &gt; /= 20 % bone marrow plasmacytosis . All necessary baseline study determine eligibility must obtain within 35 day prior registration . Patients must performance status 02 base SWOG criteria.Patients poor performance status ( 34 ) , base solely bone pain , eligible . Patients must platelet count &gt; = 100,000/microliters . Patients platelet count &lt; 100,000/microliters may enrol felt due extensive marrow plasmacytosis . The study coordinator must consult dose modification may apply . All patient must inform investigational nature study must sign give write informed consent accordance institutional federal guideline . Patients must receive prior autotransplant allograft . Patients must significant comorbid medical condition uncontrolled life threaten infection . Patients recent ( &lt; o= 6 month ) myocardial infarction , unstable angina , difficult control congestive heart failure , uncontrolled hypertension , difficult control cardiac arrythmias ineligible . Ejection fraction ECHO MUGA within institutional normal range must perform within 42 day prior registration . Patients must history chronic obstructive chronic restrictive pulmonary disease.Patients must adequate pulmonary function study &gt; = 50 % predict mechanical aspect ( FEV1 , FVC , etc ) diffusion capacity ( DLCO ) &gt; = 50 % predict . Patients unable complete pulmonary function test due myeloma related pain fracture must high resolution CT scan chest must also acceptable arterial blood gas define P02 great 70 . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient disease free least three year . Prior malignancy acceptable provide evidence disease within threeyear interval must prior treatment cytotoxic drug could potentially assign treatment protocol . Pregnant nursing woman may participate . Women childbearing potential must negative pregnancy document within one week registration . Women/men reproductive potential may participate unless agree use effective contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>D.T . PACE</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Transplant</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Interferon-alpha 2b</keyword>
	<keyword>Sargramostim</keyword>
</DOC>